Compare Moderna, Inc. (MRNA) vs BlackRock TCP Capital Corp (TCPC) Price & Performance

Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.

The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.

TCPC trades at $4.07, showing no daily change. The stock exhibits bearish technical signals with flat support/resistance at $4. Recent earnings showed mixed results with Q2 2026 beating estimates at $0.22 EPS versus $0.20 expected. The company faces fundamental challenges with negative revenue of -$77.27M and net income of -$88.93M for 2025, though it maintains a dividend payout of $0.17 quarterly.

Investment outlook remains cautious due to negative profitability metrics and ongoing strategic review. The company's portfolio sale and leverage reduction provide some stability, but persistent revenue declines and class action lawsuits present significant risks. Analyst consensus leans neutral with 61.5% hold ratings, reflecting uncertainty about the company's turnaround prospects.